Advertisement
U.S. markets open in 8 hours 29 minutes

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
123.97+0.92 (+0.75%)
At close: 04:00PM EDT
119.00 -4.97 (-4.01%)
After hours: 04:41PM EDT

Sarepta Therapeutics, Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000
https://www.sarepta.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees1,314

Key Executives

NameTitlePayExercisedYear Born
Mr. Douglas S. Ingram Esq.President, CEO & Director1.62MN/A1963
Mr. Ian Michael EstepanExecutive VP & CFO917.53kN/A1976
Dr. Louise R. Rodino-Klapac Ph.D.Executive VP, Chief Scientific Officer and Head of Research & Development1.04MN/A1978
Mr. Ryan E. Brown J.D.Executive VP, General Counsel & Corporate Secretary823.36kN/A1978
Mr. Bilal ArifExecutive VP & Chief Technical Operations OfficerN/AN/A1972
Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsN/AN/AN/A
Ms. Alison NasisiExecutive VP & Chief People OfficerN/AN/AN/A
Dr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerN/AN/AN/A
Mr. Dallan MurrayExecutive VP & Chief Customer OfficerN/AN/AN/A
Mr. Will TiltonSenior VP, Head of Strategy & Chief of StaffN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Sarepta Therapeutics, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 6. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.